Available in the shop
- Tirzepatide 5 mg — $94.50
- Tirzepatide 10 mg — $136.50
- Tirzepatide 15 mg — $172.20
- Tirzepatide 20 mg — $197.40
- Tirzepatide 30 mg — $231.00
- Tirzepatide 40 mg — $294.00
Sold for in vitro laboratory research only — not for human or animal consumption. ≥99% purity specification.
Identification
| Field of research | Weight research |
|---|---|
| Formula | C225H348N48O68 |
| Molecular weight | 4813 g/mol |
| Also known as | Zepbound, tirzepatida, tirzepatidum, OYN3CCI6QE, RefChem:58651, BG-121, GTPL11429, FT181880, FT182420, Tirzepatide sodium salt (LY3298176)? |
| PubChem | CID 156588324 |
Summary
Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist.
From Wikipedia, available under CC BY-SA 4.0. Short description from Wikidata (CC0).
Published research
Titles are shown as published. Listing a paper is not an endorsement of its findings, and many papers on research peptides are laboratory or animal studies: the type of study is shown when PubMed records it.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical TrialClinical Trial, Phase IIIMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov'tAronne LJ, Sattar N, Horn DB et al. · JAMA, 2024 · PMID 38078870 · DOI
- Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trialsSystematic ReviewNetwork Meta-AnalysisKaragiannis T, Malandris K, Avgerinos I et al. · Diabetologia, 2024 · PMID 38613667 · DOI
- Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection FractionComparative StudyObservational StudyKrüger N, Schneeweiss S, Fuse K et al. · JAMA, 2025 · PMID 40886075 · DOI
- Tirzepatide: A Review in Type 2 DiabetesReviewFrance NL, Syed YY · Drugs, 2024 · PMID 38388874 · DOI
- Tirzepatide as Compared with Semaglutide for the Treatment of ObesityClinical Trial, Phase IIIComparative StudyEquivalence TrialMulticenter StudyAronne LJ, Horn DB, le Roux CW et al. · N Engl J Med, 2025 · PMID 40353578 · DOI
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesClinical Trial, Phase IIIComparative StudyEquivalence TrialMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov'tFrías JP, Davies MJ, Rosenstock J et al. · N Engl J Med, 2021 · PMID 34170647 · DOI
- Tirzepatide for overweight and obesity managementReviewHamza M, Papamargaritis D, Davies MJ · Expert Opin Pharmacother, 2025 · PMID 39632534 · DOI
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trialClinical Trial, Phase IIIRandomized Controlled TrialRosenstock J, Wysham C, Frías JP et al. · Lancet, 2021 · PMID 34186022 · DOI
Top 8 of 2,584 results, by relevance. See all on PubMed.
Search query "Tirzepatide"[Title/Abstract]
Data provenance
| Data | Source | Record |
|---|---|---|
| Chemical identity and structure | PubChem | CID 156588324 |
| Published literature | PubMed | Search on PubMed |
| Summary sentence | Wikipedia | Tirzepatide |
Data retrieved 2026-10-08. See About for the sources. How the data is collected and checked: Methods.